---
layout: post
title: New Drug Approvals 2013 - Pt. XVII - Flutemetamol F18 (VizamylTM)
date: '2013-11-03T19:33:00.001Z'
author: Rita
tags:
- Small Molecule Drugs
- 2013 New Drugs
- Diagnostic Agents
- Radiopharmaceuticals
- Parenteral Drugs
- Imaging Agents
modified_time: '2013-11-03T19:33:36.742Z'
thumbnail: http://1.bp.blogspot.com/-lRBc8-TPCes/UnOGjAZThpI/AAAAAAAAA64/Wq85dvdkuqo/s72-c/CHEMBL2042122.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-7582039450475800869
blogger_orig_url: http://chembl.blogspot.com/2013/11/new-drug-approvals-2013-pt-xvii.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://www.trademarkia.com/logo-images/ge-healthcare-limited/vizamyl-85328526.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="150" src="http://www.trademarkia.com/logo-images/ge-healthcare-limited/vizamyl-85328526.jpg" width="400" /></a></div>
<center face="arial">
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,1,0,2,0,0,1,0,0,1" width="400" /></center>
<br />
<div style="text-align: center;">
<b>ATC Code:</b> <a href="http://www.whocc.no/atc_ddd_index/?code=V09AX04">V09AX04</a><br />
<br /></div>
<div style="text-align: justify;">
On October 25<sup>th</sup>, the FDA approved Flutemetamol F18 (Tradename: <a href="http://www.trademarkia.com/vizamyl-85328526.html">Vizamyl</a>; Research Code: [<sup>18</sup>F]AH110690 ), a radioactive diagnostic agent, for intravenous (i.v.) use in <a href="http://en.wikipedia.org/wiki/Positron_emission_tomography">Positron Emission Tomography</a> (PET) imaging of the brain in adult patients with <a href="http://en.wikipedia.org/wiki/Cognitive_impairment">cognitive impairment</a>, who are being evaluated for <a href="http://en.wikipedia.org/wiki/Alzheimer%27s_disease">Alzheimer’s disease (AD)</a> and dementia.</div>
<br />
<div style="text-align: justify;">
Alzheimer's disease is a non-treatable, progressively worsening and fatal disease, characterised by a decrease in cognitive functions, such as memory, and is usually associated with an accumulation of <a href="http://en.wikipedia.org/wiki/Beta_amyloid">β amyloid</a> (Uniprot: <a href="http://www.uniprot.org/uniprot/P05067">P05067</a>) plaques in several brain regions. These deposits are believed to be responsible for cellular damage and ultimately cell death.</div>
<br />
<div style="text-align: justify;">
Flutemetamol F18 is the second approved diagnostic drug to estimate β-amyloid neuritic plaque density, after the approval of <a href="http://chembl.blogspot.co.uk/2012/04/new-drug-approvals-2012-pt-ix.html">Florbetapir F18</a> in 2012. Like  Florbetapir F18, Flutemetamol F18 binds to β amyloid plaques in the brain where the F-18 isotope produces a positron signal that can be detected by a PET scanner. The advantages of this compound over its predecessor are: exposure to a lower dose of radiation; and more time for PET image acquisition (20 vs. 10 minutes). In in vitro binding studies using postmortem human brain homogenates containing fibrillar β amyloid, the dissociation constant (Kd) for flutemetamol was 6.7 nM.</div>
<br />
<div style="text-align: justify;">
<span style="font-family: inherit;">It is worth mentioning, that a positive scan, indicating the presence of β amyloid deposits, it's not enough to diagnose a patient with Alzheimer's disease, since these protein deposits can also be present in patients with other types of dementia, or in elderly people without any neurological disease. However, a negative scan, where little or none β-amyloid plaques can be detected, indicates that the cause for dementia is probably not due to Alzheimer's disease. </span></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-lRBc8-TPCes/UnOGjAZThpI/AAAAAAAAA64/Wq85dvdkuqo/s1600/CHEMBL2042122.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://1.bp.blogspot.com/-lRBc8-TPCes/UnOGjAZThpI/AAAAAAAAA64/Wq85dvdkuqo/s320/CHEMBL2042122.png" /></a></div>
<br />
<div style="text-align: justify;">
Flutemetamol F18 (IUPAC Name: 2-[3-fluoranyl-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol; Canonical smiles: CNc1ccc(cc1[18F])c2nc3ccc(O)cc3s2 ; ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2042122">CHEMBL2042122</a>; PubChem: <a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=15950376">15950376</a>; ChemSpider: <a href="https://www.chemspider.com/Chemical-Structure.13092196.html">13092196</a>; Standard InChI Key: VVECGOCJFKTUAX-HUYCHCPVSA-N) is a synthetic small molecule with a radioactive isotope of fluorine (<sup>18</sup>F), with a molecular weight of 274.3 Da, 3 hydrogen bond acceptors, 2 hydrogen bond donors, and has an ALogP of 3.61. The compound is therefore fully compliant with the rule of five.</div>
<br />
<div style="text-align: justify;">
Flutemetamol F18 is available as a radioactive solution for intravenous injection and the recommended imaging dose is 185 megabecquerels (MBq) [5 millicuries(mCi)] in a total volume of 10 mL or less. Following intravenous injection, the plasma concentrations declines by approximately 75% in the first 20 minutes post-injection, and by approximately 90% in the first 180 minutes. Flutemetamol F18 metabolites are primarily excreted via the hepatobiliary (52%) and the renal system (37%). </div>
<br />
<div style="text-align: justify;">
The license holder for Vizamyl<sup>TM</sup> is <a href="http://www.gehealthcare.com/">GE Healthcare</a>, and the full prescribing information can be found <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203137s000lbl.pdf">here</a>.</div>
